Investor Presentaiton

PDT Portfolio Revenue Growth of +10-20% at CER Expected in FY22 Driven by Strong Demand and Stable Supply • CAPACITY EXPANSION Takeda Fastest and strongest post-pandemic recovery of donation volumes in the industry On track to increase plasma supply and manufacturing capacity >65% by end FY2023¹ • Dedicated R&D organization focused on maximizing potential of PDT R&D INVESTMENT • Positive Phase 3 data for HyQvia in CIDP . Improving efficiencies across the entire value chain to improve profitability MARGIN IMPROVEMENT • Reduced donor compensation by >15% in H1 FY2022 versus same period in prior year Enhancement of PDT operations is driving double-digit annual revenue growth for key PDT products PDT IMMUNOLOGY REVENUE GROWTH IMMUNOGLOBULIN REVENUE GROWTH (@CER) ALBUMIN REVENUE GROWTH (@CER) (@CER) +10-20% CAGR +11% CAGR +11% +10-20% CAGR +14% +10-20% FY2018 FY2021 FY2022 (projection) FY2018 FY2021 FY2022 (projection) FY2018 FY2021 FY2022 (projection) 7 1. Versus calendar year 2018 baseline

View entire presentation